FMISO Imaging for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
Is FMISO imaging safe for humans?
How is the drug ¹⁸F-Fluoromisonidazole (¹⁸F-FMISO) unique for brain cancer treatment?
¹⁸F-Fluoromisonidazole (¹⁸F-FMISO) is unique because it is a radiotracer used in PET scans to detect low-oxygen areas (hypoxia) in tumors, which can help doctors understand how the cancer might respond to treatments like radiotherapy and chemotherapy. This approach is different from standard treatments as it provides detailed imaging of tumor oxygen levels, which is crucial for planning effective treatment strategies.13678
What data supports the effectiveness of the drug 18F-Fluoromisonidazole (FMISO) for brain cancer?
Who Is on the Research Team?
Ramon Barajas
Principal Investigator
OHSU Knight Cancer Institute
Are You a Good Fit for This Trial?
This trial is for adults over 18 with known or suspected brain tumors who can consent to the study. They should have a performance score indicating they're fairly active and able to care for themselves, and either planning or have had treatment for their tumor. Pregnant individuals, those with severe kidney issues, claustrophobia, certain allergies, or conditions where oxygen therapy could be harmful are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Imaging
Participants receive FMISO intravenously and undergo dynamic and static PET/CT or PET/MRI scans to assess tumor oxygen levels and imaging metrics.
Retest Examination
Participants undergo a retest examination within 7 days to assess reproducibility of imaging metrics.
Follow-up
Participants are monitored for safety and effectiveness of imaging metrics, with potential additional scans every 4 weeks.
What Are the Treatments Tested in This Trial?
Interventions
- ¹⁸F-Fluoromisonidazole
¹⁸F-Fluoromisonidazole is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
OHSU Knight Cancer Institute
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Weill Cornell University
Collaborator
Oregon Health and Science University
Collaborator